News - Page 172 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”

COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”

Post published:June 30, 2021
Post category:Press Release

Read more about the article Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Post published:June 29, 2021
Post category:Press Release

Read more about the article Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Post published:June 28, 2021
Post category:Press Release

Read more about the article COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

Post published:June 28, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications

Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications

Post published:June 28, 2021
Post category:Press Release

Read more about the article MindMed Included in FTSE Russell 3000® Index

MindMed Included in FTSE Russell 3000® Index

Post published:June 28, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Ex-FDA Psychiatry Director Joins Cybin as Advisor; Texas Approves Psychedelics Studies; and more…

Psychedelic Bulletin: Ex-FDA Psychiatry Director Joins Cybin as Advisor; Texas Approves Psychedelics Studies; and more…

Post published:June 25, 2021
Post category:Psychedelic Bulletin

Read more about the article UK Set to Become Hub of Psychedelic Research, as British Startup Gears-up to Run Trials for International Psychedelic Drug Developers

UK Set to Become Hub of Psychedelic Research, as British Startup Gears-up to Run Trials for International Psychedelic Drug Developers

Post published:June 25, 2021
Post category:Press Release

Read more about the article Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Post published:June 24, 2021
Post category:Press Release

Read more about the article Wesana Health Partners with University of South Carolina

Wesana Health Partners with University of South Carolina

Post published:June 24, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.